Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Slides:

Advertisements

Similar presentations

Figure 2. Positive selection of J15 TCR transgenic T cells specific for H60. (A) CD4 by CD8 profiles (left) of thymocytes and numbers (right) of each thymic.

Advertisements

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Uptake of T-MPs for DC maturation and antigen presentation.

MP cells, but not pathogen-elicited effector CD4+ T lymphocytes, rapidly produce IFN-γ during T. gondii infection independently of pathogen antigens. MP.

Nonclassical monocytes are specifically depleted following M-CSFR inhibition and these cells are highest in PD-L1 expression in blood of mice during therapy.

Depletion of CD169+ cells leads to increased expression of CD25 on enterotoxin A–specific Vβ3+ T cells. Depletion of CD169+ cells leads to increased expression.

CD1dhiCD5+ B cells are expanded in pancreatic neoplasia and are functionally important for sustaining growth of KrasG12D-PDEC in vivo. CD1dhiCD5+ B cells.

MP cells are generated from naïve cells in the periphery.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

Tregs and APC subsets in TDLNs of patients with cervical cancer.

Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

mpJX-594 effects on tumor burden and leukocyte influx.

PD-1–PD-L1 axis is highly expressed and is not IFNγ-dependent in a subcutaneous murine model of PDA. A, experimental design for establishment of subcutaneous.

Src acetylation is critical for its tumorogenesis property.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

MP cells are generated from naïve cells in the periphery.

MP cells, but not pathogen-elicited effector CD4+ T lymphocytes, rapidly produce IFN-γ during T. gondii infection independently of pathogen antigens. MP.

The number of islet antigen–specific T cells is reduced in CT-treated RIP-LCMV-GP mice. The number of islet antigen–specific T cells is reduced in CT-treated.

Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors. Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors.

Interacting MDSCs and mast cells (MC) in human colon carcinoma and in the colon of AOM/DSS-induced tumor-bearing mice. Interacting MDSCs and mast cells.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.

CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.

CD11bhighCD27high conventional NK cells are converted into MDSCs

BLITC reporter for monitoring of GvHD.

IL6 mRNA is not detected in metastatic prostate cancer cells.

Β-Cryptoxanthin at a concentration of 10 μmol/L decreases proliferation in HCT116 cells after 6 and 8 days of treatment. β-Cryptoxanthin at a concentration.

M-Wnt and E-Wnt cells cluster tightly with claudin-low and basal-like breast tumors, respectively, by microarray analysis. M-Wnt and E-Wnt cells cluster.

Vascular staining in CWR22R xenograft tumors.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

5FU-induced specific activation of CD8+ T cells.

CD4+ and CD8+ TILs express surface CD137.

Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy by Julia K. Tietze, Danice.

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

TILs upregulate CD137 in an HIF-1α–dependent fashion.

Circulating leukocytes are undetectable in blood vessels of solid tumors in RIP1-Tag2 mice even after IL-15/IL-15Rα complex treatment. Circulating leukocytes.

CD4+ cells are required to generate protective immunity against the MT-HA tumor in HA104 mice. CD4+ cells are required to generate protective immunity.

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

In vivo bioluminescence imaging of primary tumors and tumor metastasis

Circulating leukocytes do not efficiently infiltrate advanced solid tumors in IL-15/IL-15Rα complex–treated RIP1-Tag2 mice. Circulating leukocytes do not.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Mice with a B cell–specific deletion of Ets1 have increased memory phenotype B cells but no increase in switching to IgG1. Mice with a B cell–specific.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. Immune response of CEA-transgenic mice.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

VEGF-A inhibition impedes proliferation in Amppos tumors.

Mice with a B cell–specific deletion of Ets1 do not have increased CD4+ T cell activation. Mice with a B cell–specific deletion of Ets1 do not have increased.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid cells. In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid.

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Meningeal γδ T cells are biased toward IL-17 production.

Fetal-derived γδ T cells infiltrate the meninges from birth.

Presentation transcript:

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. A, kinetics of BrdUrd incorporation in spleen, lymph node, and tumors of control and IL-15/IL-15Rα complex–treated RIP1-Tag2 mice. BrdUrd incorporation among CD8+ cells was assessed at 24-h intervals throughout the treatment. *, P < 0.05, Student's t test. Data are representative of two independent experiments (n = 6 individual mice per time point). B, histogram depicts BrdUrd+ cells among CD8+ cells in spleen, lymph nodes, and tumors at day 3. C, expression of surface CD122 and CD44 by CD8+ T cells in spleens and tumors of control and IL-15/IL-15Rα complex–treated RIP1-Tag2 mice. Values in dot plots indicate percentage of gated cells among CD8+ T cells. Mathieu Epardaud et al. Cancer Res 2008;68:2972-2983 ©2008 by American Association for Cancer Research